Xueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patients

Active, not recruitingOBSERVATIONAL
Enrollment

21,600

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 30, 2024

Conditions
Venous Thromboembolism (VTE)Thromboembolism
Trial Locations (14)

100000

China-Japan Friendship Hospital, Beijing

214500

Jingjiang Chinese Medicine Hospital, Jingjiang

253000

Qilu Hospital of Shandong University Dezhou Hospital, Dezhou

410000

The Third Hospital of Changsha, Changsha

510000

Guangzhou Red Cross Hospital, Guangzhou

523000

Dongguan Chinese Medicine Hospital, Dongguan

528000

Foshan Hospital of Traditional Chinese Medicine, Foshan

530000

The First People's Hospital of Nanning, Nanning

537000

Yulin Second People's Hospital, Yulin

543000

The People's Hospital of Wuzhou, Wuzhou

Wuzhou Red Cross Hospital, Wuzhou

545000

The First Affiliated Hospital of Guangxi Medical University, Liuzhou

050000

Hebei General Hospital, Shijiazhuang

0635 252000

Liaocheng People's Hospital, Liaocheng

All Listed Sponsors
collaborator

Guangxi Wuzhou Pharmaceutical (GROUP) Co., Ltd.

UNKNOWN

lead

China-Japan Friendship Hospital

OTHER

NCT06443905 - Xueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patients | Biotech Hunter | Biotech Hunter